Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343499 · ClinicalTrials.gov registry record · Phase 4
The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)
A Phase 4 study, sponsored by Intermountain Health Care.
- Terminated
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT00343499 is a Phase 4 study that was terminated before completion, run by Intermountain Health Care. The registered enrollment target is 200 participants.
The verdict
NCT00343499, a Phase 4 study, was terminated before completion, sponsored by Intermountain Health Care.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
24 week, single center, prospective, randomized, double-blind treatment study of valsartan (80 mg/bid, increased to 160 mg/bid) or placebo in addition to other general medical therapy in patients with persistent atrial fibrillation (AF) undergoing electrical cardioversion to restore normal sinus rhythm (SR).
Interventions
- DRUG valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343499
The ClinicalTrials.gov registry entry for NCT00343499 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valsartan is the first listed.
NCT00343499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343499 about?
NCT00343499 is a clinical study titled "The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)". 24 week, single center, prospective, randomized, double-blind treatment study of valsartan (80 mg/bid, increased to 160 mg/bid) or placebo in addition to other general medical therapy in patients with persistent atrial fibrillation (AF) undergoing electrical cardioversion to restore normal sinus rhy...
What is the current status of trial NCT00343499?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2004-11. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00343499?
The interventions under investigation include: valsartan (DRUG).
Who is sponsoring clinical trial NCT00343499?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.